Diffuse Alveolar Hemorrhage With Avelumab Maintenance Therapy.

acute hypoxemic respiratory failure diffuse alveolar hemorrage ground-glass opacity immune check-point inhibitor urothelial malignancy

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Jun 2021
Historique:
accepted: 21 06 2021
entrez: 26 7 2021
pubmed: 27 7 2021
medline: 27 7 2021
Statut: epublish

Résumé

Immune checkpoint blockade is a rapidly expanding therapeutic modality in oncology. However, its adverse effects extend beyond the cytotoxicity of conventional chemotherapy. Pneumotoxicity associated with immune checkpoint therapy presents a diagnostic conundrum that has been further complicated by the COVID-19 pandemic. We report a case of a patient with metastatic urothelial carcinoma who developed diffuse alveolar hemorrhage (DAH) following treatment with avelumab.

Identifiants

pubmed: 34306873
doi: 10.7759/cureus.15805
pmc: PMC8294017
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e15805

Informations de copyright

Copyright © 2021, Li et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Thorac Cancer. 2018 Nov;9(11):1522-1524
pubmed: 30253076
Cancer Immunol Immunother. 2017 May;66(5):551-564
pubmed: 28213726
Onco Targets Ther. 2018 Sep 17;11:5879-5883
pubmed: 30271171
Case Rep Oncol. 2020 Jun 22;13(2):696-701
pubmed: 32774259
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Curr Probl Diagn Radiol. 2014 May-Jun;43(3):128-39
pubmed: 24791616
Lung Cancer. 2018 Aug;122:22-24
pubmed: 30032835
N Engl J Med. 2020 Sep 24;383(13):1218-1230
pubmed: 32945632
Ann Oncol. 2017 Mar 1;28(3):583-589
pubmed: 27998967
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Respir Med Case Rep. 2020 Jun 11;30:101131
pubmed: 32577370
Cancer. 2018 May 1;124(9):2010-2017
pubmed: 29469949
Immunol Allergy Clin North Am. 2012 Nov;32(4):587-600
pubmed: 23102067
Chest. 2010 May;137(5):1164-71
pubmed: 20442117
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
Lancet Oncol. 2017 May;18(5):587-598
pubmed: 28373007
J Clin Oncol. 2017 Mar;35(7):785-792
pubmed: 28068177
Am J Respir Crit Care Med. 1995 Jan;151(1):157-63
pubmed: 7812547

Auteurs

Si Li (S)

Internal Medicine, The Wright Center for Graduate Medical Education, Scranton, USA.

Nishant Sharma (N)

Internal Medicine, The Wright Center for Graduate Medical Education, Scranton, USA.

Daniel Kazmierski (D)

Internal Medicine, The Wright Center for Graduate Medical Education, Scranton, USA.

Mohammad Asim Amjad (MA)

Internal Medicine, The Wright Center for Graduate Medical Education, Scranton, USA.

Yishan Dong (Y)

Internal Medicine, Rochester Regional Health, Rochester General Hospital, Rochester, USA.

Yichen Wang (Y)

Mercy Internal Medicine Service, Trinity Health of New England, Springfield, USA.

Namita Sharma (N)

Hematology and Oncology, Geisinger Commonwealth School of Medicine, Scranton, USA.

Srinivasarao Ramakrishna (S)

Pulmonary and Critical Care Medicine, Geisinger Commonwealth School of Medicine, Scranton, USA.

Pius Ochieng (P)

Pulmonary and Critical Care Medicine, Geisinger Commonwealth School of Medicine, Scranton, USA.

Classifications MeSH